Clene Inc.
No SEC Form 4 filings for $CLNN in the last 30 days.
See all $CLNN insider activity →Clene Inc. (CLNN) announced a $4M direct offering of 1.22M shares at $3.28 each, expected to close on September 17, 2026. The company plans to use the funds for corporate purposes, including regulatory activities and CNM-Au8 development. CLNN stock closed at $3.28 on Monday, down 8.12%, and is up 11.71% in pre-market trading.
Clene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.
Clene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter of 2026 ● Clene announces survival and functional
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLNN (Clene Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CLNN coverage spans financial news, corporate actions and regulation.
The capital raise dilutes existing shareholders but secures runway, likely supporting short-term price stability.
Potential FDA approval could unlock significant upside for CLNN.
Regulatory pathway clarity and new NfL biomarker analyses increase the probability of an accelerated-approval NDA review, a key binary catalyst for CLNN.
Chidozie Ugwumba's 9.7% stake in Clene Inc. suggests increased insider interest, potentially signaling confidence or strategic positioning.
Significant insider selling of Clene Inc. shares suggests possible profit-taking or reduced confidence among major shareholders.
AlphAI scores every news story that mentions CLNN with an AI model for sentiment and relevance, and aggregates insider trades from Clene Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Clene Inc. (CLNN) announced a $4M direct offering of 1.22M shares at $3.28 each, expected to close on September 17, 2026. The company plans to use the funds for corporate purposes, including regulatory activities and CNM-Au8 development. CLNN stock closed at $3.28 on Monday, down 8.12%, and is up 11.71% in pre-market trading.
2 min readClene (CLNN) plans to submit an NDA for its ALS drug in Q4, following FDA-requested biomarker analyses. The company reported consistent neurofilament reductions across trials and believes its data links biomarker changes to clinical benefits. Clene aims for an FDA decision by year-end and a potential commercialization decision by early 2027.
2 min readClene Inc. (CLNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CLENE REPORTS Second QUARTER 2026 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS ● Clene expects to submit a New Drug Application for CNM-Au8 ® in ALS under the accelerated approval pathway in early fourth quarter of 2026 ● Clene announces survival and functional
6 min readChidozie Ugwumba has reported a 9.7% beneficial ownership stake in Clene Inc. (CLNN), totaling 1,351,071 shares. This includes both issued common stock and shares issuable upon the exercise of immediately exercisable Tranche A, Tranche B, and Common Stock Purchase Warrants. The filing is an amendment to a Schedule 13G and references 12,778,307 shares outstanding as of May 14, 2026, as per Clene Inc.'s Form 10-Q.
2 min readSymBiosis II LLC, an entity associated with major Clene (NASDAQ: CLNN) shareholder Ugwumba Chidozie, reported selling a total of 78,679 shares of Clene Inc. common stock in two open-market transactions. These sales occurred on May 1, 2026, for 5,795 shares at $6.01, and on May 4, 2026, for 72,884 shares at $6.80. Following these transactions, SymBiosis II LLC indirectly holds 198,890 shares of Clene Inc.
3 min readA 10% owner of Clene (NASDAQ: CLNN), through the associated entity SymBiosis II, LLC, sold 19,497 shares of common stock in open-market transactions over three days in late April 2026. The sales were executed at prices ranging from $5.63 to $6.08 per share. Following these transactions, SymBiosis II, LLC still indirectly holds 277,569 shares of Clene Common Stock.
3 min readA Form 144 filing indicates that Symbiosis II LLC has reported multiple proposed and executed sales of Common Stock in Clene Inc. (NASDAQ: CLNN) during January–March 2026. The filing details numerous open-market dispositions, including 31,297 shares sold on March 31, 2026, for $152,316.52 and 32,705 shares sold on January 12, 2026, for $179,867.17, with individual trade sizes and cash amounts provided for each transaction. This filing provides transparency into Symbiosis II LLC's recent trading activities in CLNN shares.
2 min readClene Inc. (CLNN) has secured an $8 million subaward for the third year of its $45.1 million NIH grant, supporting an Expanded Access Program for CNM-Au8 in amyotrophic lateral sclerosis (ALS). This agreement with New York University covers the period from September 1, 2025, to August 31, 2026, with reimbursements against invoices. Clene maintains full control over its background intellectual property, granting no licenses to NYU or the U.S. government, while ensuring confidentiality for proprietary data.
2 min readUgwumba Chidozie, a ten percent owner of Clene Inc. (NASDAQ:CLNN), sold 32,474 shares of common stock for approximately $161,519 in three transactions between January 16 and January 21, 2026. These sales, conducted indirectly through Symbiosis II, LLC, leave Chidozie's entity still owning 617,824 shares. The company has also secured over $28 million in funding and received an FDA Type C meeting for its ALS drug candidate CNM-Au8, with Benchmark reiterating a Buy rating.
4 min readChidozie Ugwumba, a major shareholder in Clene Inc. (NASDAQ:CLNN), sold 7,030 shares of the company's stock on December 16th, which was part of a larger series of trades between December 4th and 18th, totaling approximately 201,218 shares. Following these transactions, Ugwumba holds 401,850 shares valued at about $2.54 million. The insider selling coincided with a 7.4% drop in CLNN shares to $6.04, amidst mixed analyst ratings and the company reporting a quarterly EPS loss.
3 min read
